TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02865967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care + a-GPS
Description: Clinicians will be provided a-GPS data on a regular basis for intervention group, but not control group such as their risk factors for asthma, quality of care, and asthma outcomes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care + a-GPS
Description: Clinicians will be provided a-GPS data on a regular basis for intervention group, but not control group such as their risk factors for asthma, quality of care, and asthma outcomes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care + a-GPS
Description: Clinicians will be provided a-GPS data on a regular basis for intervention group, but not control group such as their risk factors for asthma, quality of care, and asthma outcomes.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The subjects will be treat for their asthma by their physicians according to usual care.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The subjects will be treat for their asthma by their physicians according to usual care.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The subjects will be treat for their asthma by their physicians according to usual care.
Study: NCT01042977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
Study: NCT03986307

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acid supplementation
Description: Daily supplementation with omega-3 capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Resistance exercise training in both supplementation conditions (3 times per week for 12 weeks).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance exercise
Description: Resistance exercise training in both supplementation conditions (3 times per week for 12 weeks).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - appearance-matched oil supplementation
Description: Daily supplementation with placebo capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g
Study: NCT00703651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion influenza vaccine
Description: 0.1 mL, ID. 1 injection/year for 3 years

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion influenza vaccine
Description: 0.1 mL, ID. 1 injection/year for 3 years.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated, split-virion influenza vaccine
Description: 0.5 mL, IM. 1 injection/year for 3 years
Study: NCT02716168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared video consultation between patient, general practitioner and oncologist
Description: At the start of the patients chemotherapy treatment a shared video consultation between the patient, general practitioner and oncologist will bee arranged. The video consultation should address distribution of roles, comorbidity, medicine, depression and anxiety symptoms, relatives and social resources.
Study: NCT03174535

Intervention type: DRUG
Intervention: Qilong capsules (QLC), produced by Jining Huaneng Pharmaceutical Factory Co., Ltd.
Description: The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks.
Study: NCT02525120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triojection
Description: Triojection is system intended to deliver a specific amount of ozone to a herniated disc.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical discectomy
Description: Patients will receive surgery to remove the herniated disc material.
Study: NCT04055701

Intervention type: OTHER
Group type: OTHER
Intervention: assesment of thymus volume
Description: assesment of thymus volume
Study: NCT04227223

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: biochemical measurements
Description: TOC,TAC, and BDNF measurements are performed using ImAnOx , PerOx and BDNF tests (Immundiagnostik, Germany)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biochemical measurements
Description: TOC,TAC, and BDNF measurements are performed using ImAnOx , PerOx and BDNF tests (Immundiagnostik, Germany)
Study: NCT04487015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MP
Description: The app-based menu planner (MP) given to the participants has an automated carbohydrate periodisation menu planning tool, an educational and motivational nutrition content (infographics, video and text articles), and recipes. Participants using the app will input their training schedule into the app to produce their own menu plans. The behaviour change techniques (BCT) underlying the intervention are goal \& planning, feedback \& monitoring, shaping knowledge, natural consequences, comparison of behaviour, comparison of outcome, associations, repetitions, reward \& threat, regulation and antecedents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MP
Description: The app-based menu planner (MP) given to the participants has an automated carbohydrate periodisation menu planning tool, an educational and motivational nutrition content (infographics, video and text articles), and recipes. Participants using the app will input their training schedule into the app to produce their own menu plans. The behaviour change techniques (BCT) underlying the intervention are goal \& planning, feedback \& monitoring, shaping knowledge, natural consequences, comparison of behaviour, comparison of outcome, associations, repetitions, reward \& threat, regulation and antecedents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MP
Description: The app-based menu planner (MP) given to the participants has an automated carbohydrate periodisation menu planning tool, an educational and motivational nutrition content (infographics, video and text articles), and recipes. Participants using the app will input their training schedule into the app to produce their own menu plans. The behaviour change techniques (BCT) underlying the intervention are goal \& planning, feedback \& monitoring, shaping knowledge, natural consequences, comparison of behaviour, comparison of outcome, associations, repetitions, reward \& threat, regulation and antecedents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MP
Description: The app-based menu planner (MP) given to the participants has an automated carbohydrate periodisation menu planning tool, an educational and motivational nutrition content (infographics, video and text articles), and recipes. Participants using the app will input their training schedule into the app to produce their own menu plans. The behaviour change techniques (BCT) underlying the intervention are goal \& planning, feedback \& monitoring, shaping knowledge, natural consequences, comparison of behaviour, comparison of outcome, associations, repetitions, reward \& threat, regulation and antecedents.
Study: NCT02010060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Individuals randomized to the aerobic exercise training group will participate in 6 months of supervised exercise training. Exercise dose (expressed in kilocalories per kg per week \[KKW\]) during aerobic training will be 8KKW in week 1, 10KKW in week 2 and 12 KKW in week 3. the exercise dose of 12KKW will be maintained throughout the intervention. Pedometers will be worn by participant in blind-mode throughout the intervention, and removed during exercise training sessions. Participants will enter information about whether they wore their pedometer on the study website. Aerobic exercise group participants will be told to make no conscious alterations to their physical activity or dietary habits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise+ Physical Activity
Description: The Aerobic Exercise+ Physical Activity Group will participate in the same supervised exercise training intervention as the Aerobic Exercise Group, but will also increase the amount of non-exercise physical activity in their daily lives. After week 6 of intervention, participants will incrementally increase Non-Ex PA until they reach an average of 3,000 steps/day above baseline. Non-Ex PA will be increased with moderate physical activity consistent with daily living (i.e. leisurely walking in the evening, walking the dog etc.). Participants will also periodically have life-style counseling sessions with instructors with expertise in behavioral change support to their dietary habits
Study: NCT01042977

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
Study: NCT00384891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synergo + MMC
Description: Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Calmette-Guérin
Description: Intravesical instillation with BCG (Bacillus Calmette-Guérin)
Study: NCT03666182

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT04634721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine injected . This will then be repeated on the contralateral side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine injected . This will then be repeated on the contralateral side.
Study: NCT00003782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Arm 1: 600 mg/m2 IV every 21 days for 4 cycles; Arm 3: 500 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Arm 1: 600 mg/m2 IV every 21 days for 4 cycles; Arm 3: 500 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Arm 1: 100 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 75 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Arm 1: 100 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 75 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Arm 1: 100 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 75 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles
Study: NCT00204750

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bougie Dilation
Description: Bougie dilation will be performed as standard

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle-knife incision
Description: Needle-knife incision will be performed
Study: NCT03807154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT
Description: A nine week long ICBT-programme with therapist guidance. Based on cognitive and behavioral techniques that have been tailored to address loneliness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT
Description: A nine week long internet-based IPT-programme with therapist guidance. Contains three distinct phases: assessment phase (three weeks), focus phase (five weeks, during which the participants will choose from one of four primary problem areas during the three latter weeks), and end phase (one week).
Study: NCT03670979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone swaging
Description: osseous wall pedicle was placed to treat the infrabony defect by autogrnous bone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone swaging
Description: osseous wall pedicle was placed to treat the infrabony defect by autogrnous bone
Study: NCT03960008

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Trans-Arterial Chemoembolization (TACE)
Description: First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubin
Description: This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
Study: NCT06576999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor-based Balance Training
Description: 10 sessions of sensor-based balance training with exergaming feedback. For this training an adaptive integrated audio-visual feedback system composed of five IMUs and a force platform connected wirelessly to a computer has been used. The training protocol include exercises of balance control, encompassing a total of five distinct exercises: i) Latero-lateral load shifting while seated; ii) Load shifting while standing: latero-lateral and antero-posterior, to simulate the balance control performed during the day; iii) Load control during sit-to-stand; iv) Gait swing and loading phase response: to stimulate a correct load shifting during the swing and stance phase; v) Latero-lateral load shifting with knee flexion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Balance Trainging
Description: 10 sessions of usual balance training. The training includes: gait control exercises, weight shifting, and relies on both stable surfaces (i.e., steps) and unstable surfaces (i.e., oscillating platforms and various-sized fitballs). The protocol encompassed the application of stabilization techniques and the reaching of targets with the upper limb during upright position emulating the activity of daily living.
Study: NCT00116974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Scaling and root planing

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing
Study: NCT00209261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MINIRIN Oral Lyophilisate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minirin tablet
Study: NCT06068101

Intervention type: DIAGNOSTIC_TEST
Intervention: Secreening test for primary aldosteronism and Confirmatory Testing
Description: Serum aldosterone and plasma direct renin concentrations were measured by a chemiluminescent immunoassay. A positive PA screening was defined by aldosterone \> or = 10 ng/dL and aldosterone to renin ratio \> or = 2 ng/dL/uUI/mL
Study: NCT01038206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Familias Unidas
Description: There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV. Consistent with our prior Familias Unidas efficacy studies, all parent group sessions and all family visits will be conducted in Spanish and will take place in the evenings and on Saturdays at the school or at a community site that is preferred by the families.
Study: NCT02464306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fidaxomicin
Description: Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days.
Study: NCT01483976

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral medical nutritional supplement
Description: orally over a three hour period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental oral medical nutritional supplement with AN777
Description: orally over a three hour period
Study: NCT03793205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting G-CSF
Description: Long-acting G-CSF will be given 48 hours after the chemotherapy. A supplement of short-acting G-CSF will be given as required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-acting G-CSF
Description: Short-acting G-CSF will be given as required 24 hours after the chemotherapy.
Study: NCT01747031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PressureWire™ Certus(St. Jude Medical Systems, Sweden)
Description: Fractional flow reserve measured during cardiac catheterization--A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden) will be advanced past the stenosis.
Study: NCT04245436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Encapsulated duloxetine 30 mg, 60 mg; once-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Encapsulated escitalopram 5 mg, 10 mg, 15 mg, 20 mg; once-daily
Study: NCT02454608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil HCl
Description: Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil HCl
Description: Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule with the same characteristics (size, color, smell) as Verapamil HCl.
Study: NCT02927236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: TBS is a type of TMS protocol.To administer the iTBS treatment, a MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil will be used.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: TBS is a type of TMS protocol.To administer the iTBS treatment, a MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil will be used.

Intervention type: DEVICE
Group type: OTHER
Intervention: TMS
Description: TBS is a type of TMS protocol.To administer the iTBS treatment, a MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: TBS is a type of TMS protocol.To administer the iTBS treatment, a MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil will be used.
Study: NCT01110551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (SC)
Description: Phosphate buffered saline administered subcutaneously.
Study: NCT01272050

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: RT in the standard arm A will be administered to a total dose of 64 Gy in 32 fractions of 2 Gy over 6.4 weeks. RT in the experimental arm B will be administered to a total dose of 70 Gy in 35 fractions of 2 Gy over 7 weeks.~Megavoltage equipments with nominal photon energies ≥ 6 MV are required. Rotational techniques such as Tomotherapy®, Rapidarc®, intensity-modulated arc technique (IMAT) and volumetric-modulated arc therapy (VMAT) will also be eligible. The patient will be treated in an isocentric setting and all fields will be applied for 5 days per week for the total RT duration.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: RT in the standard arm A will be administered to a total dose of 64 Gy in 32 fractions of 2 Gy over 6.4 weeks. RT in the experimental arm B will be administered to a total dose of 70 Gy in 35 fractions of 2 Gy over 7 weeks.~Megavoltage equipments with nominal photon energies ≥ 6 MV are required. Rotational techniques such as Tomotherapy®, Rapidarc®, intensity-modulated arc technique (IMAT) and volumetric-modulated arc therapy (VMAT) will also be eligible. The patient will be treated in an isocentric setting and all fields will be applied for 5 days per week for the total RT duration.